Clinical Trial Update: Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

View source ↗

Summary

This update announces the availability of an Expanded Access Program for Neladalkib (NVL-655) for patients with advanced ALK-positive non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Neladalkib (neladalkib)

Snippet

Sponsor: Nuvalent Inc. | Conditions: Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC) | Status: AVAILABLE